Drugs / Dapirolizumab pegol
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04571424 | Oct 2020 → Apr 2021 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01764594 | Jan 2013 → Aug 2014 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01093911 | Mar 2010 → Dec 2012 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02804763 | Jun 2016 → May 2018 | systemic lupus erythematosus | UCB Biopharma S.P.R.L. | Completed | Missed primary |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06617325 | Nov 2024 → May 2028 expected | systemic lupus erythematosus | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 3 | NCT04976322 | Jul 2021 → Aug 2030 expected | systemic lupus erythematosus | UCB Biopharma SRL | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04294667 | Aug 2020 → May 2024 | systemic lupus erythematosus | UCB Biopharma SRL | Completed | Met primary |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | UCB Pharma | Results EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus ucb.com ↗
In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE |
| 2026-06-04 | Biogen | Results EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus biogen.com ↗
In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE |
| 2026-06-01 | UCB Pharma | Results UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus ucb.com ↗
The results showed statistically significant improvement in disease activity with DZP added to standard of care (SOC) versus placebo plus standard of care. |
| 2026-06-01 | Biogen | Results UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus biogen.com ↗
Findings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid tapering |
| 2025-06-12 | UCB Pharma | Results Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activit ucb.com ↗
In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. |
| 2025-06-12 | Biogen | Results Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity biogen.com ↗
In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. |
| 2024-11-19 | UCB Pharma | Results Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity ucb.com ↗
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE). |
| 2024-11-19 | Biogen | Results Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity biogen.com ↗
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity |
| 2024-09-24 | UCB Pharma | Results UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 ucb.com ↗ |
| 2024-09-24 | Biogen | Results UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 biogen.com ↗ |
| 2018-10-23 | Biogen | Results UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus biogen.com ↗
The primary endpoint of the study to demonstrate a dose response at 24 weeks on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) was not met (p=0.06). |
All press releases naming this drug 12 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dapirolizumab pegol | “The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant...” NCT04294667 ↗5“We investigated the safety and clinical activity of dapirolizumab pegol, a polyethylene glycol conjugated anti-CD40L Fab' fragment, in patients with SLE.” PMID 28780512 ↗ Aug 2017 “Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.” NCT06617325 ↗ |
| Known as | BIIB133 | “BIIB133 (Dapirolizumab pegol)” NCT04571424 ↗ |
| Known as | CDP7657 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01093911 ↗ |
| Known as | DZP | “The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant...” NCT04294667 ↗3“Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.” NCT06617325 ↗ “Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks” NCT02804763 ↗ “DZP” NCT04571424 ↗ |
| Action | Inhibit | “CD40L blockade might provide an innovative treatment for systemic autoimmune disorders.” PMID 28780512 ↗ Aug 2017 |
| Modality | Monoclonal antibody | — CHEMBL2109478 ↗ |
| Modality | Protein / enzyme biologic | “a polyethylene glycol conjugated anti-CD40L Fab' fragment” PMID 28780512 ↗ Aug 2017 |
| Route | Intravenous | “CDP7657 IV” PMID 25784719 ↗ Mar 2015 |
| Target | CD40LG | “a PEGylated anti-CD40L antibody fragment” PMID 25784719 ↗ Mar 2015 |